These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38822092)

  • 1. An injectable, nanostructured implant for the delivery of adenosine triphosphate: towards long-acting formulations of small, hydrophilic drugs.
    Giacalone G; Quaillet M; Huang N; Nicolas V; Boulogne C; Gillet C; Fattal E; Bochot A; Hillaireau H
    Drug Deliv Transl Res; 2024 Aug; 14(8):2146-2157. PubMed ID: 38822092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable Nanoparticles-Loaded PLGA Microcapsule for the Enhanced Encapsulation Efficiency and Controlled Release of Hydrophilic Drug.
    Ryu S; Park S; Lee HY; Lee H; Cho CW; Baek JS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33801871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable long-acting systems for Radix Ophiopogonis polysaccharide based on mono-PEGylation and in situ formation of a PLGA depot.
    Shi X; Lin X; Zheng X; Feng Y; Shen L
    Int J Nanomedicine; 2014; 9():5555-63. PubMed ID: 25489243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically established biodegradable long acting injectables: An industry perspective.
    Nkanga CI; Fisch A; Rad-Malekshahi M; Romic MD; Kittel B; Ullrich T; Wang J; Krause RWM; Adler S; Lammers T; Hennink WE; Ramazani F
    Adv Drug Deliv Rev; 2020 Dec; 167():19-46. PubMed ID: 33202261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
    Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
    Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-situ forming PLGA implants: Towards less toxic solvents.
    Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
    Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs.
    Manna S; Donnell AM; Kaval N; Al-Rjoub MF; Augsburger JJ; Banerjee RK
    Int J Pharm; 2018 Aug; 547(1-2):122-132. PubMed ID: 29857096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of penetration potential of pH responsive double walled biodegradable nanogels coated with eucalyptus oil for the controlled delivery of 5-fluorouracil: In vitro and ex vivo studies.
    Sahu P; Kashaw SK; Jain S; Sau S; Iyer AK
    J Control Release; 2017 May; 253():122-136. PubMed ID: 28322977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mPEG-PLGA on Drug Crystallinity and Release of Long-Acting Injection Microspheres: In Vitro and In Vivo Perspectives.
    Xing D; Tang L; Yang H; Yan M; Yuan P; Wu Y; Zhang Y; Yin T; Wang Y; Gou J; Tang X; He H
    Pharm Res; 2024 Jun; 41(6):1271-1284. PubMed ID: 38839720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo skin permeation and retention studies on chitosan-ibuprofen-gellan ternary nanogel prepared by in situ ionic gelation technique--a tool for controlled transdermal delivery of ibuprofen.
    Abioye AO; Issah S; Kola-Mustapha AT
    Int J Pharm; 2015 Jul; 490(1-2):112-30. PubMed ID: 25997660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery.
    Thalhauser S; Peterhoff D; Wagner R; Breunig M
    Eur J Pharm Biopharm; 2020 Nov; 156():1-10. PubMed ID: 32860903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
    Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
    AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo.
    Nieto K; Mallery SR; Schwendeman SP
    Int J Pharm; 2020 Aug; 586():119475. PubMed ID: 32525080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries.
    Elkasabgy NA; Abdel-Salam FS; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkheshen SA
    Int J Pharm; 2019 Nov; 571():118703. PubMed ID: 31536761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
    Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
    Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Step Preparation of pH-Responsive Polymeric Nanogels as Intelligent Drug Delivery Systems for Tumor Therapy.
    Li Y; Bui QN; Duy LTM; Yang HY; Lee DS
    Biomacromolecules; 2018 Jun; 19(6):2062-2070. PubMed ID: 29625005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancement in nanogel formulations provides controlled drug release.
    Ahmed S; Alhareth K; Mignet N
    Int J Pharm; 2020 Jun; 584():119435. PubMed ID: 32439585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N‑methyl‑2‑pyrrolidone as solvent.
    Kamali H; Khodaverdi E; Hadizadeh F; Mohajeri SA
    Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():561-575. PubMed ID: 30606566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merits of sponge-like PLGA microspheres as long-acting injectables of hydrophobic drug.
    Kim S; Sah H
    J Biomater Sci Polym Ed; 2019 Dec; 30(18):1725-1743. PubMed ID: 31443621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled release of a model hydrophilic high molecular weight compound from injectable non-lamellar liquid crystal formulations containing different types of phospholipids.
    Okada A; Todo H; Hijikuro I; Itakura S; Sugibayashi K
    Int J Pharm; 2020 Mar; 577():118944. PubMed ID: 31870952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.